Melanie J. Davies, MD; Richard Bergenstal, MD; Bruce Bode, MD; et al.
This randomized trial reports that, among overweight and obese participants with type 2 diabetes, use of daily liraglutide, a glucagon-like peptide 1 analog, resulted in weight loss over 56 weeks compared with placebo.